Abstract
Given the demonstrated importance of the incretin effect on the prandial insulin response, augmentation of the incretin effect in people with type 2 diabetes is an important pharmacological approach to glycemic management. In recent years, the use of incretin-based therapies, such as GLP-1 receptor agonists and DPP-4 inhibitors, has increased dramatically due to their demonstrated efficacy, low risk of hypoglycemia when used as monotherapy, and reasonable tolerability. Given their effects on glycemic parameters and the likelihood of aiding in weight loss, GLP-1 receptor agonists provide a unique treatment option for people with type 2 diabetes. Increased clinical experience and study of incretin-based therapies will help answer questions about safety issues that have arisen from post-marketing reports. The potential benefit of incretin-based therapies in the treatment of people with type 2 diabetes and cardiovascular disease is currently an active area of inquiry. While the potential benefits of incretin-based therapies in the arena of cardiovascular risk reduction are promising, results from ongoing outcomes-based studies will help determine the role of these agents in this setting.
Keywords: Dipeptidyl peptidase-4, DPP-4 inhibitors, GLP-1 receptor agonists, Glucagon-like peptide-1 (GLP-1), Glucose-dependent insulinotropic peptide (GIP), Incretin effect, Incretin mimetics, Pharmacotherapy, Type 2 diabetes mellitus (T2DM)
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Incretin Pharmacology: A Review of the Incretin Effect and Current Incretin-Based Therapies
Volume: 10 Issue: 4
Author(s): Joshua J. Neumiller
Affiliation:
Keywords: Dipeptidyl peptidase-4, DPP-4 inhibitors, GLP-1 receptor agonists, Glucagon-like peptide-1 (GLP-1), Glucose-dependent insulinotropic peptide (GIP), Incretin effect, Incretin mimetics, Pharmacotherapy, Type 2 diabetes mellitus (T2DM)
Abstract: Given the demonstrated importance of the incretin effect on the prandial insulin response, augmentation of the incretin effect in people with type 2 diabetes is an important pharmacological approach to glycemic management. In recent years, the use of incretin-based therapies, such as GLP-1 receptor agonists and DPP-4 inhibitors, has increased dramatically due to their demonstrated efficacy, low risk of hypoglycemia when used as monotherapy, and reasonable tolerability. Given their effects on glycemic parameters and the likelihood of aiding in weight loss, GLP-1 receptor agonists provide a unique treatment option for people with type 2 diabetes. Increased clinical experience and study of incretin-based therapies will help answer questions about safety issues that have arisen from post-marketing reports. The potential benefit of incretin-based therapies in the treatment of people with type 2 diabetes and cardiovascular disease is currently an active area of inquiry. While the potential benefits of incretin-based therapies in the arena of cardiovascular risk reduction are promising, results from ongoing outcomes-based studies will help determine the role of these agents in this setting.
Export Options
About this article
Cite this article as:
J. Neumiller Joshua, Incretin Pharmacology: A Review of the Incretin Effect and Current Incretin-Based Therapies, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (4) . https://dx.doi.org/10.2174/187152512803530379
DOI https://dx.doi.org/10.2174/187152512803530379 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets
Current Drug Targets Preface
Current Rheumatology Reviews Macrophages in Immunopathology of Atherosclerosis: A Target for Diagnostics and Therapy
Current Pharmaceutical Design Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Controversies in Pharmacological Treatment of Inflammatory Component of Macular Edema
Current Pharmaceutical Design Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Modulation of Eosinophil Functions by Nitric Oxide: Cyclic GMPdependent and -independent Mechanisms
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry TNF-Alpha Antagonism in Severe Asthma?
Recent Patents on Inflammation & Allergy Drug Discovery Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Current Therapeutic Approaches in Inflammatory Bowel Disease
Current Pharmaceutical Design Role of Endothelial Progenitor Cell Mobilization After Percutaneous Angioplasty Procedure
Current Pharmaceutical Design Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Anterior Uveitis with Negative Work-up: Giant Cell Arteritis Remains the Pet Peeve
Current Rheumatology Reviews A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews